Fixed-dose combination ceftolozane / tazobactam (Zerbaxa) for the treatment of complicated intra-abdominal infections


The fixed-dose combination ceftolozane / tazobactam (trade name: Zerbaxa) has been approved in Germany since September 2015 for the treatment of complicated infections inside the abdomen (complicated intra-abdominal infections) in adults.

An inside the abdomen may be caused by bacteria entering the abdomen through the gastrointestinal tract, for example as the result of an injury or surgery. The can spread further from there. This type of is called a complicated intra-abdominal .

Complicated intra-abdominal infections may become life-threatening. If possible, the infected tissue is surgically removed and are used.

The fixed-dose combination ceftolozane / tazobactam is an antibiotic: Ceftolozane kills , and tazobactam enhances this effect by attacking an enzyme that would otherwise inactivate ceftolozane.


The fixed-dose combination ceftolozane / tazobactam is given every 8 hours in the form of an infusion into the bloodstream (IV drip). The dose for complicated intra-abdominal infections is 1 g ceftolozane and 0.5 g tazobactam. Depending on the course of the disease, the treatment is stopped after 4 to 14 days.

The dose is lowered in patients who have moderately to severely impaired kidney function or terminal kidney failure.

Depending on which are involved, other may be used as well.

Other treatments

Adults who have a complicated intra-abdominal can have treatment with individualized antibiotic therapy. Individualized antibiotic therapy takes into account the local occurrence of germs, (local) resistances to , the risk of by multiresistant and the sensitivity of the to the .


In 2020, the Institute for Quality and Efficiency in Health Care (IQWiG, Germany) looked into the advantages and disadvantages of the fixed-dose combination ceftolozane / tazobactam when compared with the standard treatments for complicated intra-abdominal infections in adults.

But the manufacturer didn’t provide any suitable data with which to do the assessment.

More information

This information summarizes the main results of a review produced by the Institute for Quality and Efficiency in Health Care (IQWiG, Germany). The review was commissioned by the German Federal Joint Committee (G-BA) as part of the “early benefit assessment of medications.” On the basis of the review and the hearings received, the G-BA passed a resolution on the added benefit of the fixed-dose combination of ceftolozane / tazobactam (Zerbaxa).

Institute for Quality and Efficiency in Health Care (IQWiG, Germany). Ceftolozane/tazobactam (complicated intra-abdominal infections)  – Benefit assessment according to §35a Social Code Book V. Dossier assessment; Commission A20-27. June 29, 2020. (IQWiG reports; Volume 938).

IQWiG health information is written with the aim of helping people understand the advantages and disadvantages of the main treatment options and health care services.

Because IQWiG is a German institute, some of the information provided here is specific to the German health care system. The suitability of any of the described options in an individual case can be determined by talking to a doctor. can provide support for talks with doctors and other medical professionals, but cannot replace them. We do not offer individual consultations.

Our information is based on the results of good-quality studies. It is written by a team of health care professionals, scientists and editors, and reviewed by external experts. You can find a detailed description of how our health information is produced and updated in our methods.

Comment on this page

What would you like to share with us?

We welcome any feedback and ideas. We will review, but not publish, your ratings and comments. Your information will of course be treated confidentially. Fields marked with an asterisk (*) are required fields.

Please note that we do not provide individual advice on matters of health. You can read about where to find help and support in Germany in our information “How can I find self-help groups and information centers?

Created on July 16, 2020
Next planned update: 2023


Institute for Quality and Efficiency in Health Care (IQWiG, Germany)

How we keep you informed

Follow us on Twitter or subscribe to our newsletter or newsfeed. You can find all of our films online on YouTube.